Key facts
- MCAL Therapeutics’s last known valuation is $24.0M (May 2025).
- It has raised $11.3M across 1 recorded rounds; the latest was Early Stage VC ($5.9M) in Mar 2024.
- Notable investors include OphthaFund.
- MCAL Therapeutics has filed 1 Form D with the SEC, most recently Mar 2024 ($5.9M sold to 29 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for MCAL Therapeutics
Funding rounds
1 roundsAbout MCAL Therapeutics
Operator of a biotechnology platform intended to treat ophthalmic diseases. The company offers a dry eye research platform advancing ophthalmology discoveries, enabling healthcare providers to address ocular conditions and improve patient care.
- Sector
- Healthcare
- HQ
- Park City, UT, United States
- Founded
- 2020
- Employees
- 3
- Website
- mcaltherapeutics.com/
- Ownership
- Privately Held (backing)
MCAL Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MCAL Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MCAL Therapeutics in its N-PORT filings yet. We sweep new filings monthly.